WISE S.p.A., a Milan-based medical device company developing implantable electrodes for neuromonitoring, neuromodulation and brain-computer interface applications, has closed an oversubscribed €30 million Series D round.
The financing adds ENEA Tech and Biomedical as a new strategic investor and follows a first closing completed in June 2024, which included a venture debt facility from the European Investment Bank backed by InvestEU, an equity investment from Wallaby S.p.A., and participation from existing investors New Frontier, Eureka Venture SGR and Indaco Ventures SGR.
WISE said the proceeds will be used to advance its Heron lead through regulatory certification and a first-in-human study, while also supporting clinical adoption and broader commercial scale-up of its electrode portfolio. The funding will also support expanded commercialization of the WISE Cortical Strip.
The round underscores continued investor interest in neurotechnology and implantable medical devices, particularly platforms aimed at both clinical validation and market expansion.
The financing adds ENEA Tech and Biomedical as a new strategic investor and follows a first closing completed in June 2024, which included a venture debt facility from the European Investment Bank backed by InvestEU, an equity investment from Wallaby S.p.A., and participation from existing investors New Frontier, Eureka Venture SGR and Indaco Ventures SGR.
WISE said the proceeds will be used to advance its Heron lead through regulatory certification and a first-in-human study, while also supporting clinical adoption and broader commercial scale-up of its electrode portfolio. The funding will also support expanded commercialization of the WISE Cortical Strip.
The round underscores continued investor interest in neurotechnology and implantable medical devices, particularly platforms aimed at both clinical validation and market expansion.